Research analysts who have asked questions during IPA earnings calls.
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
3 questions for IPA
Also covers: ABSI, BSEM, CGEN +24 more
RS
Ramakanth Swayampakula
H.C. Wainwright & Co., LLC
2 questions for IPA
Also covers: AEMD, CORT, HUMA +1 more
DB
Daby Benjamine Carreras
Spartan Capital Securities, LLC
1 question for IPA
RF
Robert Farrell
Scarlet Knight Capital
1 question for IPA
Will McHale
Ingalls & Snyder
1 question for IPA
Recent press releases and 8-K filings for IPA.
MindWalk Reports Q2 FY 2026 Earnings and Strategic Updates
IPA
Earnings
Management Change
New Projects/Investments
- MindWalk, formerly IPA, completed a divestiture that generated approximately $14.3 million in net proceeds and rebranded with a new stock ticker, $HYFT.
- For Q2 FY 2026, MindWalk reported $4,124 thousand CAD in revenue, $2,662 thousand CAD in gross profit, and an adjusted EBITDA of -$2,422 thousand CAD.
- The company maintained a strong cash balance of $16,508 thousand CAD as of Q2 FY 2026.
- MindWalk expanded its leadership team with the appointment of Scott Areglado as Chief Financial Officer and Dr. Thomas Lynch as Chief Business Officer.
- Strategic asset development includes the MindWalk Vault™ Asset GLP-1, which is in IND-enabling planning, and a Dengue Vaccine, advancing preclinical planning.
Dec 15, 2025, 3:30 PM
MindWalk Reports Strong Q2 Fiscal Year 2026 Financial Results and Strategic Progress
IPA
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
Management Change
- MindWalk (formerly ImmunoPrecise Antibodies) reported Q2 Fiscal Year 2026 revenue of CAD 4.1 million, marking a 54% year-over-year increase and 30% sequential growth, representing record quarterly revenue from continuing operations. Gross profit increased 94% to CAD 2.7 million, achieving a 65% gross margin for continuing operations.
- The company strengthened its balance sheet by divesting non-core wet lab operations in the Netherlands, which generated approximately $14.3 million in net proceeds and contributed to ending the quarter with $16.5 million in cash.
- MindWalk is advancing its GLP-1 and dengue vaccine programs using its Bio-Native AI platform, LensAI, and is establishing a Cayman Islands-based segregated portfolio structure for AI-generated assets to attract capital partners and avoid shareholder dilution.
- Scott Areglado was appointed Chief Financial Officer and Dr. Thomas Lynch was appointed Chief Business Officer.
Dec 15, 2025, 3:30 PM
MindWalk Reports Strong Q2 2026 Financials, Completes Divestiture, and Establishes New Funding Structure
IPA
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- MindWalk (formerly ImmunoPrecise Antibodies) reported strong Q2 2026 financial results, with revenue increasing 54% year-over-year to CAD 4.1 million and gross profit rising 94% to CAD 2.7 million, achieving a 65% gross margin for continuing operations.
- The company completed the divestiture of non-core wet lab operations in the Netherlands, generating approximately $14.3 million in net proceeds and bolstering its cash position to $16.5 million.
- MindWalk has rebranded and unified its operations under the MindWalk identity with HYFT as its Nasdaq ticker, aligning its corporate structure with its BioNative AI strategy.
- To fund its AI-generated assets, such as GLP-1 and dengue vaccine programs, the company is establishing a segregated portfolio structure in the Cayman Islands to allow direct asset-level investment and avoid diluting the parent company.
- MindWalk clarified it has not been buying back shares and that a CAD 30 million at-the-market (ATM) facility is a potential future tool, not an active fundraising effort, as it prioritizes asset-level investments to protect shareholders from dilution.
Dec 15, 2025, 3:30 PM
MindWalk Reports Strong Q2 2026 Financial Performance and Strategic Restructuring
IPA
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- MindWalk (formerly ImmunoPrecise Antibodies) reported Q2 fiscal year 2026 revenue of $4.1 million, marking 54% year-over-year growth, and a 94% increase in gross profit to $2.7 million, achieving a 65% gross margin for continuing operations.
- The company completed the divestiture of non-core wet lab operations in the Netherlands, generating $14.3 million in net proceeds and strengthening its cash position to $16.5 million.
- MindWalk is establishing a segregated portfolio structure in the Cayman Islands to house and finance individual AI-generated assets, allowing direct investor participation at the asset level and providing an alternative funding mechanism to protect against shareholder dilution.
- The company appointed Scott Arriglato as Chief Financial Officer and Dr. Thomas Lynch as Chief Business Officer to support its software-led BioNative AI business strategy.
- MindWalk is advancing internal programs, including GLP-1 and longevity programs and a dengue vaccine initiative, leveraging its patented HYFT patterns and LENSai platform.
Dec 15, 2025, 3:30 PM
ImmunoPrecise Antibodies Rebrands as MindWalk, Announces NASDAQ Ticker Change
IPA
New Projects/Investments
- ImmunoPrecise Antibodies Ltd. has rebranded as MindWalk, unifying its subsidiaries BioStrand and Talem under this single corporate brand.
- The company's NASDAQ ticker symbol will change from IPA to HYFT.
- This rebrand signifies an evolution into a Bio-Native AI platform business, built at the intersection of AI, multi-omics data, and advanced laboratory research.
- MindWalk is transitioning its business model from standalone wet-lab services to an integrated, scalable platform company model, launching DaaS and SaaS offerings, and enabling large-scale partnerships.
Sep 3, 2025, 1:21 PM
Quarterly earnings call transcripts for IPA.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more